Ecuador - spaniolă - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

celltrion, inc. corea, republica de - rituximab 10 mg/ml - concentrado para soluciÓn para perfusiÓn - cada ml contiene: rituximab 10 mg

Uniunea Europeană - spaniolă - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Uniunea Europeană - spaniolă - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - inmunosupresores - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Peru - spaniolă - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

farmindustria s.a. - clorhidrato de memantina; - tableta recubierta - por ; rituximab 100.000000 mcg; - rituximab

Peru - spaniolă - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

promociones farmaceuticas s.a. en liquidacion - por ; rituximab 10.000000 mg; - rituximab

Peru - spaniolă - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

astrazeneca peru s.a. - comprimido - por ; rituximab 100.000000 mg; - rituximab

Spania - spaniolă - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 5 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán

Spania - spaniolă - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 25 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán

Spania - spaniolă - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

regiomedica gmbh - irinotecan hidrocloruro trihidrato - excipientes: sorbitol,hidroxido de sodio (e-524) - otros agentes antineoplÁsicos - otros agentes antineoplásicos - irinotecán

Spania - spaniolă - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

pfizer s.l. - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 5 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán